Found 25 matching trials
A Safety and Pharmacokinetic Study of Proellex® PHASE1 Dose escalating study of 7 daily doses of Proellex at 100 mg, 150 mg and 20...
Show More Location
Healthcare Discoveries Inc.
Learn More & Join Trial
Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003 PHASE2 ZPU-003 EXT is a 2-year extension study of ZPU-003 (NCT00882258) to determi...
Show More Location
Women's Health Research
Learn More & Join Trial
Crossover Study of the Safety and PK Properties of Proellex® PHASE1 Study to evaluate the PK of 25 mg and 50 mg of Proellex from 2 different su...
Show More Location
Healthcare Discoveries Inc.
Learn More & Join Trial
A Multi-Center, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids PHASE2 The primary objective of this study is to determine the safety and efficacy...
Show More Location
Alabama Clinical Therapeutics, LLC
Learn More & Join Trial
Safety and Efficacy of Proellex in Pre-menopausal Anemic Women With Symptomatic Uterine Fibroids PHASE3 Eligible female subjects will be randomly assigned to one of the three trea...
Show More Location
Alabama Clinical Therapeutics
Learn More & Join Trial
Safety and Efficacy of Telapristone Acetate (Proellex®) in the Treatment of Pre-Menopausal Women With Confirmed, Symptomatic Endometriosis PHASE2 The primary purpose of this study is to determine the safety and efficacy o...
Show More Location
Multiple Locations
Learn More & Join Trial
Open-Label Extension Study to ZPE-202 PHASE2 This study is a phase 2, open-label extension study of 12 mg Proellex for 2...
Show More Location
Multiple Locations
Learn More & Join Trial
Safety and Efficacy of Proellex in Pre-Menopausal Anemic Women With Symptomatic Uterine Fibroids PHASE3 Subjects will be randomly assigned to one of 3 treatment groups and receive...
Show More Location
Hospital Perinatal del Estado de Mexico del ISEM
Learn More & Join Trial
Safety of 25 and 50 mg Proellex® in the Treatment of Women With Symptomatic Uterine Fibroids PHASE3 Safety and efficacy study of 25 and 50 mg doses of Proellex...
Location
Visions Clinical Research
Learn More & Join Trial
Safety, Pharmacokinetics and Efficacy of Proellex® (Telapristone Acetate) Administered Vaginally in the Treatment of Premenopausal Women With Uterine Fibroids Who Have Completed ZPV-200 PHASE2 To further determine the safety and efficacy of Proellex in premenopausal w...
Show More Location
Multiple Locations
Learn More & Join Trial